Fig. 1From: Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancera Time to PSA progression-free survival according to the percentage change in the PSA level at 12 weeks. b Overall survival according to the percentage change in the PSA level at 12 weeksBack to article page